The company is divided into three basic business units: pharmaceuticals, medical devices and consumer products. Sales of prescription drugs account for half of J & J revenue generated in 2018 at $ 81.58 billion.
Pharmaceutical sales continued to shine for J & J in the quarter. Sales reached $ 10.19bn, surpassing the $ 9.99bn expected. The anti-inflammatory treatment Stelara achieved better than expected sales of 1.44 billion dollars while Simponi fell to 482 million dollars compared to the average estimate of 573.3 million dollars, according to StreetAccount data
. quarter-on-quarter revenue, surpassing StreetAccount's expectations of $ 695.5 million. The judge last year canceled a Zytiga patent, allowing generic versions to enter the market. Despite the success of Zytiga in the quarter, some investors worry that losing the patent will undermine future sales, said Jeffreys analyst Jared Horz, quoted by CNBC. Sales of baby care products that include baby powder, washing and lotions have fallen to $ 473 million from $ 490 million in the fourth quarter of 201
His medical device segment continued to fight. Sales amounted to $ 6.67 billion, down from Wall Street by $ 6.68 billion, down more than 4 percent from $ 6.97 billion in the same period last year. A December report from Reuters reported that J & J has known for decades talc baby in dust containing asbestos. The company has repeatedly denied any abuse and is behind its baby powder name
As Reuters publishes its report, J & J shares have fallen by about 9.5%. Analysts call the congestion of sales, saying that any risk of litigation would cost less than billions of dollars lost in market capitalization. "Gorski said on Tuesday.